Sonoma Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed Jun 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 16, 2026
SNOA$1.13+1.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Financial Statements and Supplementary Data
ITEM 8. Consolidated Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB No. 215) | F-1 |
|---|---|
| Consolidated Balance Sheets as of March 31, 2026 and 2025 | F-2 |
| Consolidated Statements of Comprehensive Loss for the Years Ended March 31, 2026 and 2025 | F-3 |
| Consolidated Statements of Changes in Stockholders’ Equity for the Years Ended March 31, 2026 and 2025 | F-4 |
| Consolidated Statements of Cash Flows for the Years Ended March 31, 2026 and 2025 | F-5 |
| Notes to Consolidated Financial Statements | F-6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.